Intellectual Property - March 9, 2022
Sigrid Therapeutics granted European patent
Sigrid Therapeutics has announced that the European Patent Office has granted the company patent titled “A porous silica material for use as a pharmaceutical or dietary active ingredient”. The patent supports use of Sigrid’s mesoporous silica particles (MSP)-based device which consists of precisely engineered micron-sized silica particles with tailored porosity designed to act locally in […]
Clinical Trials - January 20, 2022
Sigrid announces proof-of-concept results
Sigrid Therapeutics has announced that the results from their Proof-of-Concept STAR study have been published in Nanomedicine. Oral administration of the company’s lead product SiPore15 to subjects with prediabetes or newly diagnosed type 2 diabetes resulted in a significant and clinically meaningful reduction in HbA1c, a key marker of glucose control, states the company. The […]
Careers article - November 30, 2021
Sana Alajmovic named Sweden’s Female Founder of the Year 2021
Sana Alajmovic, founder and CEO of Sigrid Therapeutics, was voted the winner of the Female Founders competition 2021 as voted for by readers of the publication Dagens Industri. “It’s a great honor, not least because many of the others nominated are my role models. It has been my goal to get more people outside the […]
Business Award - June 14, 2021
Sana Alajmovic named Female Leader of the Future
The CEO of Sigrid Therapeutics, Sana Alajmovic, has both been named one of the Female Leaders of the Future and won the Life Science category of the Nova 111 list. The aim with the list is to find the most talented professionals younger than 36 years of age by ability and potential, regardless of gender […]
Agreement - June 2, 2021
Sigrid Therapeutics enters manufacturing deal
Sigrid Therapeutics has signed a collaboration agreement with the Japanese company AGC Si-Tech. “Discussions with AGC have been underway for years, and we’re very satisfied that we’ve now landed an agreement and managed to scale up manufacturing of SiPore15,” says Sana Alajmovic, CEO, Sigrid Therapeutics. Increased interest in the market While there are no approved […]
Intellectual Property - July 1, 2020
Sigrid Therapeutics obtains US patent
Sigrid Therapeutics has been granted a US patent by the United States Patent and Trademark Office (USPTO) covering the use of the company’s mesoporous silica particles (MSP)-based device SiPore15 for lowering of body fat, prevention and treatment of obesity. “This granted patent further strengthens Sigrid’s global IP portfolio while significantly enlarging the commercial attractiveness of […]
